Focus: Connect Biopharma is a public immunology-focused biopharmaceutical company developing treatments for autoimmune diseases and inflammation, headquartered in San Diego with a lean operational footprint.
Profile data last refreshed 8h ago · AI intelligence enriched 2mo ago
Suitable for immunology specialists seeking Phase 2/3 exposure in autoimmune disease with manageable cash-runway risk, but limited headcount growth.
Multiple peak-stage NDA entries suggest mature, revenue-generating utility product.
Help build intelligence for Connect Biopharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Connect Biopharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Launch-phase entry indicates recent or pending market entry.
Connect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope - Fierce Biotech
Connect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope Fierce Biotech
Connect Biopharma (CNTB) asthma trial cuts failures 66% but misses main goal - Stock Titan
Connect Biopharma (CNTB) asthma trial cuts failures 66% but misses main goal Stock Titan
An asthma drug reduced treatment failures 66%—but missed statistical significance - Stock Titan
An asthma drug reduced treatment failures 66%—but missed statistical significance Stock Titan
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference GlobeNewswire
We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate - simplywall.st
We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate simplywall.st
Mapping China’s biotech titans - Tech in Asia
Mapping China’s biotech titans Tech in Asia
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Eosinophil Counts in Adults With Asthma Treated with Anti-IL-4Rα Rademikibart: Exploratory Analyses in a Randomized Trial.
Crystal structure and molecular dynamics simulations of rademikibart Fab-IL-4Rα complex reveal biochemical basis for next-generation potent IL-4Rα inhibition in type 2 allergic and inflammatory diseases.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo